A Hormone-Free

Revolution in Birth Control

Proven Safe and Effective

Phexxi is 86% effective with typical use; typical use includes women who may not have correctly followed the Instructions for Use during the clinical trial.

Phexxi is 93% effective at preventing pregnancy when used as directed by a healthcare provider.

A Hormone-Free

Revolution in Birth Control

Why Phexxi?

EASE OF USE

Easily insert 0-60 min
before each
act of intercourse

IN THE MOMENT

Only use it when
you need it

EASY TO GET

Prescribed by a
healthcare provider

For Those Who…

HORMONE-FREE

Want to be free
of added hormones

MEDICAL REASONS

Are contraindicated
to hormones for
a medical reason

FAMILY PLANNING

Need flexibility
in family planning

Learn more about Phexxi’s Mechanism of Action

What Users Say

Hear from the Phexxi Community

If you are a Patient and want to
learn more CLICK HERE.

If you are a Health Care Professional
and want to learn more CLICK HERE.

What the Experts Say

“During my 15-year career at the FDA, I participated in the review and approval of many sexual and reproductive health products, and I believe that Phexxi serves a true unmet need in contraception. Phexxi offers women protection and control—on their terms, and at their discretion—without the use of hormones.”

Lisa Rarick, M.D., FACOG
Former FDA Division Director
Director, Evofem Biosciences

“There have been a limited number of advances in birth control over the last two decades; Phexxi represents an important step forward in women’s health. Many of my patients have cycled through numerous contraceptive options and still have not found the right fit for their sexual and reproductive needs. Phexxi offers women freedom from hormones and control over how they choose to prevent pregnancy. I look forward to offering this new on-demand option to my patients.”

Michael A. Thomas, M.D.
Chair of the Department of
Obstetrics and Gynecology
University of Cincinnati College of Medicine

“Evofem has developed an innovation in contraception that will benefit female cancer patients during and long after their treatment ends.”

Michael J. Reff
Founder and Executive Director, NCODA

Learn more about Evofem’s Product Pipeline